STTK earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -11.14. Updated 2026-07-23.
Shattuck Labs (STTK) Research Hub
Shattuck Labs (STTK) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 6.2 USD (-2.05%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -11.14, market cap 0.33B. This hub links to the full technical, earnings and options research available for STTK.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.2 USD (-2.05%) |
| 52-week range | 4.35 USD – 8.15 USD |
| Trend regime | Range |
| 14-day RSI | 33.6 (Bearish) |
| Trailing P/E | -11.14 |
| Market cap | 0.33B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for STTK
Covered Call on STTK: how it works, illustrative setup around the real 6.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on STTK: how it works, illustrative setup around the real 6.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on STTK: how it works, illustrative setup around the real 6.2 USD price, max profit/loss, breakeven and when to use it. Educational.
STTK technical analysis: range, last 6.2 USD, RSI 33.6, 52w range 4.35 USD–8.15 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is STTK in?
Shattuck Labs (STTK) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is STTK in an uptrend or downtrend?
As of 2026-09-11, STTK is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is STTK's trailing P/E ratio?
STTK's trailing P/E is -11.14, with a market cap of 0.33B. See the earnings research page for full valuation detail.
When does STTK next report earnings?
STTK is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.15 USD.